JBIO | Ticker Profile - Titan Protect

JBIO

Jade Biosciences, Inc.

Healthcare · Biotechnology · NCM

$16.94

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

LIMITED

Data Confidence: 42.9%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$39.00

+130% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

https://jadebiosciences.com

Country: United States Employees: 55 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.108

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0238

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.819

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-81.2%

Historical annualised return based on price data

Max Drawdown

-99.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

251

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$28.00

39% below the year high

52W Low

$6.57

158% above the year low

Avg Volume

586,426

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

9.0%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.63

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.29

Conservative use of debt — low financial risk

Current Ratio

14.29

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

13.96

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-95,097,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$45.00

Target Median

$39.00

Target Low

$24.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go